ArticleESMO gastrointestinal oncology2025

WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD).

K Shimozaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.